Objective The lack of randomized controlled trials (RCTs) in pulmonary fibrosis in systemic
sclerosis (SSc) has hampered an evidence‐based approach to treatment. This RCT was …

Objective. Pulmonary fibrosis is a common feature of systemic sclerosis (SSc) and a major
cause of morbidity and mortality. Since alveolitis may be an essential step in the …

Objective Pulmonary fibrosis, a frequent manifestation of systemic sclerosis (SSc), is
considered incurable. Our aim was to assess the effect of therapy with intravenous (iv) …

Objectives: Pulmonary fibrosis is a leading cause of death in systemic sclerosis (SSc). This
report examines the differences at baseline and over 12 months between patients with …

OBJECTIVE: To evaluate the safety and efficacy of monthly intravenous pulses of
cyclophosphamide (CP) in combination with low or high doses of prednisolone in patients …

OBJECTIVE: To document the effectiveness, including the longterm effect, of a course of
intravenous (IV) pulses of methylprednisolone (MP) and cyclophosphamide (CYC) in …

Objective. This retrospective observational study attempted to determine whether any of the
therapies used in the management of systemic sclerosis (SSc) patients held potential benefit …

Introduction The purpose of the present study was to systematically review the effect of
cyclophosphamide treatment on pulmonary function in patients with systemic sclerosis and …

Background The Scleroderma Lung Study (SLS) demonstrated significant treatment-
associated improvements in pulmonary function and symptoms when patients with …

Objective To evaluate the effects and safety of 6-month intravenous cyclophosphamide
(CYC) followed by 18-month oral azathioprine (AZA) therapy in patients with systemic …